Method for making multispecific antibodies having heteromultimeric and common components

• US 8,642,745 B2
• Filed: 12/08/2006
• Issued: 02/04/2014
• Est. Priority Date: 05/02/1997
• Status: Expired due to Fees

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Arathoon, W. Robert, Carter, Paul J., Merchant, Anne M., Presta, Leonard G.
• Primary Examiner(s): Yu, Misook
• Assistant Examiner(s): HOLLERAN, ANNE L
• Application Number:
  US11/608,673
• Publication Number:
  US 20070178552A1
• Time in Patent Office: 2,615 Days
• Field of Search: 530/387.3, 530/387.1, 530/387.2, 530/412, 530/413, 530/415, 530/416, 530/417, 536/23.53, 435/328, 435/69.1, 435/69.6, 435/69.7, 435/70.1, 435/71.1, 435/972
• US Class Current: 530/417
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 1/22 Affinity chromatography or related techniques based upon selective absorption processes
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2812 against CD4
• CPC Class Codes: C07K 16/2863 against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 16/46 Hybrid immunoglobulins hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: Y10S 435/972 Modified antibody, e.g. hybrid, bifunctional

Abstract

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.

Claims

1. A method of measuring the formation of a heteromeric multispecific antibody from a mixture of polypeptides, wherein the heteromeric multispecific antibody comprises four polypeptides, wherein the first polypeptide and the second polypeptide of the four polypeptides each comprise a heavy chain constant domain and a heavy chain variable domain, and the third polypeptide and the fourth polypeptide of the four polypeptides are each common light chains that are identical to each other;

wherein the first polypeptide and the third polypeptide form a binding domain that binds a first antigen, and wherein the second polypeptide and the fourth polypeptide form a binding domain that binds a different antigen;

wherein the first polypeptide and the second polypeptide each further comprise a multimerization domain,

wherein the multimerization domain of either the first polypeptide or the second polypeptide, or of both the first polypeptide and the second polypeptide, is altered by amino-acid substitution to form a non-naturally occurring disulfide bond between a free thiol-containing residue in the multimerization domain of the first polypeptide and a free thiol-containing residue in the multimerization domain of the second polypeptide;

wherein the first and second polypeptides dimerize by interaction of the first and second multimerization domains to form the heteromeric multispecific antibody;

the method comprising the steps of;

(i) causing the mixture of polypeptides from which the heteromeric multispecific antibody is formed to migrate in a gel matrix, and

(ii) determining the relative amount of a migrating band corresponding to the heteromeric multispecific antibody having a non-naturally occurring disulfide bond between the first and second polypeptides, and a slower migrating band corresponding to a heteromultimer lacking a non-naturally occurring disulfide bond between the first and second polypeptide.

2. The method of claim 1, wherein the multimerization domains further comprise a protuberance-into-cavity interaction between the first and second polypeptides.

3. The method of claim 2, wherein the method further comprises before step (i):

expressing from a first nucleic acid the first polypeptide, wherein the first nucleic acid is altered to encode an amino acid residue having a larger side chain volume, thereby generating a protuberance on the first polypeptide multimerization domain, and

expressing from a second nucleic acid the second polypeptide, wherein the second nucleic acid is altered to encode an amino acid residue having a smaller side chain volume, thereby generating a cavity on the second polypeptide multimerization domain wherein the protuberance is positioned to interact with the cavity.

4. The method of claim 3, wherein the step of altering the first or the second nucleic acid to generate a protuberance or generating a cavity, or both, occurs by phage display selection.

5. The method of claim 3, wherein the amino acid residue having a larger side chain volume than the substituted amino acid is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), tryptophan (W), isoleucine (I) and leucine (L).

6. The method of claim 3 wherein the amino acid residue having a smaller side chain volume than the substituted amino acid is selected from the group consisting of glycine (G), alanine (A), serine (S), threonine (T), and valine (V), and wherein the import residue is not cysteine (C).

7. The method of claim 1, wherein the multimerization domain is at least a part of a C_H3 domain region of an antibody constant domain, and the non-naturally occurring disulfide bond is between the C_H3 multimerization domains of the first and second polypeptides.

8. The method of claim 1, wherein the heavy chain constant domain is the heavy chain constant domain of an IgG.

9. The method of claim 8 wherein the IgG is a human IgG.

10. The method of claim 1, wherein the heavy chain constant domain is a C_H3 domain.

11. The method of claim 10 wherein the C_H3 domain is a human C_H3 domain.